Previous issue | Volume 86 | ESPE2016 | Next issue

55th Annual ESPE (ESPE 2016)

Paris, France
10 Sep 2016 - 12 Sep 2016

Card image cap
Paris, France: 10-12 September 2016 Further information

hrp0086rfc15.1 | Late Breaking | ESPE2016

A Novel Homozygous Mutation in the Domain AF-2 of Alpha Estrogen Receptor Gene (ESR1), Generating a Bio-Inactive ERα Mutant, Resulting in Estrogen Resistance with Complex Metabolic Phenotype

Feigerlova Eva , Laurell Henrik , Mittre Herve , Kottler Marie-Laure , Deshayes Marc , Balaguyer Patrick , Arnal Jean-Francois , Marechaud Richard , Hadjadj Samy , Gourdy Pierre

Context: The mouse ERα−/− knock-out model and rare human ESR1 gene mutations identified to date have demonstrated crucial role of ERα in control of energy homeostasis and glucose metabolism. Subjects with ERα deficiency show features of estrogen resistance (ESTRR) with continuous linear growth in adulthood.Patient: We describe a 20-year-old female, with unknown family history, who presented...

hrp0086rfc15.2 | Late Breaking | ESPE2016

NR0B1 Frameshift Mutation in a Boy with Precocious Puberty and Normal Adrenal Function

Shima Hirohito , Yatsuga Shuichi , Nakamura Akie , Sano Shinichiro , Sasaki Takako , Katsumata Noriyuki , Suzuki Erina , Ogata Tsutomu , Fukami Maki

Background: While hemizygous NR0B1 (DAX1) mutations usually lead to adrenal crisis during infancy or early childhood, p.Gln37*, p.Trp39*, and some other mutations result in late-onset or latent adrenal insufficiency. A small percentage of boys with NR0B1 mutations develops precocious puberty in addition to adrenal insufficiency.Objective and hypotheses: To report a boy with an NR0B1 mutation who exhibited central precocious puberty without adren...

hrp0086rfc15.3 | Late Breaking | ESPE2016

Abstract withdrawn....

hrp0086rfc15.4 | Late Breaking | ESPE2016

The Effect of Sfrp5, Wnt5a, Adiponectin, and Chemerin on Blood Pressure Regulation in Obese Children

Xiao Yan , Yin Yan

Background: The dysregulation of adipocytokines with increasing fat mass may directly contribute to hypertension. It has been confirmed that chemerin and adiponectin can affect BP. However, the effect of other adipocytokines on the development of hypertension is still poorly understood.Objective and hypotheses: The aim was to evaluate the associations of Sfrp5 and Wnt5a with blood pressure (BP), and to examine whether BP can be influenced by changes in a...

hrp0086rfc15.5 | Late Breaking | ESPE2016

Effect of Melatonin on Proliferation and Differentiation of Human Dental Pulp Cells

He Hongwen , Liu Qin , Huang Fang , Zhang Fuping

Background: Melatonin is known to regulate a variety of biological processes. The investigation and application of melatonin in oral development have got a lot of attention. The study was performed to investigate the effects of melatonin on development of human dentin formation.Objective and hypotheses: To investigate the role of melatonin in proliferation and differentiation of human dental pulp cells(hDPCs).Method: HDPCs were obt...

hrp0086rfc15.6 | Late Breaking | ESPE2016

Safety of GH in Paediatrics: The GeNeSIS Prospective Observational Study Experience between 1999 and 2015 (NCT01088412)

Blum Werner , Child Christopher , Chrousos George , Cummings Elisabeth , Deal Cheri , Hasegawa Tomonobu , Holterhus Paul-Martin , Jia Nan , Lawrence Sarah , Linglart Agnes , Loche Sandro , Maghnie Mohamad , Sanchez Jacobo Perez , Polak Michel , Predieri Barbara , Richter-Unruh Annette , Rosenfeld Ron , Tajima Toshihiro , Yeste Diego , Yorifuji Tohru

Background: Although GH’s safety profile since 1987 is good, concerns remain regarding cancer (CA) risk, and French SAGhE data indicated increased mortality and cerebrovascular disease (CVD) in certain GH-treated patients (pts).Objective and hypotheses: To evaluate key safety outcome incidence in GH-treated pts of all short stature diagnoses (dx) who participated in GeNeSIS (1999–2015, 30 countries).Methods: Pt history/ca...

hrp0086rfc15.7 | Late Breaking | ESPE2016

Long-Term Safety and Effectiveness of Daily and Weekly Growth Hormone Treatment in Pediatric GHD Patients (4-Years’ Results)

Chung Sochung , Hwang Il Tae , Rhie Young Jun , Kim Jae Hyun , Chae Hyun-Wook , Choi Jin Ho , Yoo Jae-ho , Shin Choong Ho

Background: The weekly sustained-release growth hormone (GH) has been approved for treatment in growth hormone deficiency (GHD). It provides a practical strategy for improving adherence.Objective and hypotheses: To evaluate the long-term safety and effectiveness of two formulations of daily (Eutropin®) and weekly (EutropinPlus®) GH in Korean pediatric GHD patients.Method: A multicenter, long-term, pr...

hrp0086rfc15.8 | Late Breaking | ESPE2016

Replacement of Male Mini-Puberty

Papadimitriou Dimitrios T. , Chrysis Dionysios , Zoupanos Georgios , Nyktari Georgia , Liakou Eleni , Papadimitriou Anastasios

Background: Hormonal replacement in boys with congenital HH remains a challenge. Micropenis has been traditionally successfully treated with 3 monthly injections of testosterone enanthate before the age of 2, but when bilateral cryptorchidism coincides, surgery is required. But even after a successful surgery, the hypoplastic testes with the deficient proliferation of immature Sertoli cells, due mainly to the lack of the male mini-puberty in the neonatal period as well as the ...